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Allogeneic hematopoietic cell transplantation
(HCT) often offers the best, and sometimes the only,
chance for cure for thousands of patients with hemato-
poietic malignancies. The effectiveness of allogeneic
HCT is, however, limited by the development of
graft-versus-host disease (GVHD), by opportunistic
infections, and by disease recurrence. Anti-T cell anti-
bodies are often used as a component of the prepara-
tive regimen before allogeneic HCT in an effort to
reduce the incidence and severity of GVHD. How-
ever, whether or not it is appropriate to include such
reagents is unclear. The following article includes
a brief summary of arguments for the inclusion of
anti-T cell antibodies provided by Dr. Bacigalupo,
a summary of arguments against their inclusion pro-
vided by Dr. Soiffer, and finally a summary of some
of the major unanswered questions.THE CASE FOR ANTI-T CELL ANTIBODIES
IN ALLOGENEIC HCT
Anti-T cell antibodies have been explored as part
of the preparative regimen because of the early days
of allogeneic HCT. In some of the earliest experi-
ments, antilymphocyte serum was the sole preparation
for transplantation. The IgG fraction of antilympho-
cyte serum was later purified to produce antilympho-
cyte globulin (ALG) or antithymocyte globulin
(ATG), the name depending on the immunizing cell
population. The immunized animal was either a horse
or rabbit. The advent of monoclonal antibodies in the
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ALG, ATG, and CAMPATH have been extensively
tested in the clinic both for prevention as well as for
treatment of acute GVHD (aGVHD). However, de-
spite their widespread use and thousands of patients
who have received these agents, the question still
remains open today: Are anti-T cell antibodies useful
as part of the transplant preparative regimen? The
uncertainty is reflected in the fact that some centers
include anti-T cell antibodies in the preparative regi-
men for almost all of their patients, while others never
use them. To answer this question, this section will
examine retrospective studies and the few prospective
trials published in the past 2 decades.
ATG
Retrospective studies
In a retrospective study conducted by the Interna-
tional Bone Marrow Transplant Registry, 386 patients
receiving ATG in their conditioning regimens were
compared with 474 not receiving ATG as GVHD
prophylaxis: grade II-IV aGVHD was 19% versus
51% (P\ .001) andGVHDgrade III-IV was 10% ver-
sus 22% (P\ .001) [1]. In smaller single-center trials,
the Hamburg group compared the outcome of good
risk myeloid leukemia patients who received a condi-
tioning regimen with (n 5 45) or without ATG
(n 5 57) [2]. Acute GVHD II-IV was seen in 20% of
ATG patients versus 47% of non-ATG patients (P 5
.004) and grade III-IV was seen in 7% versus 32%
(P 5 .002). The Alberta, Canada, group completed
a matched pair analysis of unrelated donor transplants
receiving ATG in the conditioning regimen with
HLA identical sibling transplants not receiving ATG
[3]. In this study, all patients received the FLUBUP
regimen (fludarabine, intravenous busulfan, peripheral
blood allogeneic stem cells). AcuteGVHDgrade II was
19% versus 36% for patients receiving or not receiving
ATG; grade III-IV was 10% versus 18%. This study
suggests that patients receiving unrelated donor pe-
ripheral blood transplants with ATGhave less aGVHD
when compared with patients receiving HLA identical
sibling peripheral blood transplants without ATG.S111
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There have been 3 randomized trials to test the
hypothesis that ATG can prevent aGVHD [4-6].
These 3 studies included a total of 166 patients: In
the 88 receiving ATG in the conditioning, the risk of
aGVHD grade II-IV was 37% versus 72% (P\ .001)
for 88 patients not receiving ATG. The risk of grade
III-IV GVHD was 11% versus 36% (P\ .001). All
3 studies came to the same conclusion: Patients ran-
domized to receive ALG/ATG have a significantly
lower risk of aGVHD.
There have been 2 trials now available with longer
follow that test the hypothesis that chronic GVHD
(cGVHD) can largely be preventedwhenATG is added
to the standard GVHD prophylaxis combination of
cyclosporine (CyA) and methotrexate (MTX) [5,7].
The first of these, the Italian Group for Marrow
Transplantation trial, involved 109 patients who
underwent an unrelated donor transplantation and
randomized patients who received or did not receive
ATG (Thymoglobulin, Genzyme, Cambridge, MA)
(7.5-15 mg/kg) in the conditioning regimen. All
patients were prepared with cyclophosphamide and
total body irradiation, followed by CyA/MTX as
GVHD prophylaxis, and all received unmanipulated
bone marrow as the stem cell source [5]. The study
was updated in 2006, looking specifically at cGVHD
in the 75 patients who survived 100 days after bone
marrow transplantation with a median follow-up of
over 2000 days. Patients randomized to the non-ATG
(n 5 37) or ATG group (n 5 38) were matched for
age, disease, and disease phase. Each patient was up-
dated for survival, cGVHD, chronic lung dysfunction
(CLD), relapse of the original disease, and quality of
life assessed by Karnofsky score.
At last follow-up, cGVHD developed in 60% ver-
sus 37% respectively, for non-ATG and ATG patients
(P 5 .05) and extensive cGVHD in 41% versus 15%
(P 5 .01). The cumulative incidence of CLD was
51% for non-ATG versus 19% for ATG patients
(P5 .005). In the non-ATG group, there was a signif-
icant decrease of FEV1 beyond 2 years (average delta
of 223%, P 5 .02) and the same was true for FVC
(average delta of 220%, P 5 .005). This was not
the case for patients receiving ATG (DFEV1: 23%,
P 5 .2; and DFVC: 13%, P 5 .3). The median
FEV1/FVC ratio was 1.02 and 1.04 for non-ATG
and ATG patients, respectively. Bidimensional plots
of FVC in the 2 groups, expressed as percent of pre-
dicted values, showed ATG patients with stable FVC
with time, whereas non-ATG patients exhibited pro-
gressive worsening of FVC, with average FVC of just
over 50%, 2500 days posttransplantation.
The proportion of patients with a Karnofsky score
of $90% in the non-ATG versus ATG patients was
28% versus 44% at 1 year (P 5 .2), 62% versus 63%at 2 years (P 5 .9), 56% versus 95% at 4 years (P 5
.005), and 57%versus 89%beyond 4 years (P5 .03) [8].
This study shows that ATG given pretransplanta-
tion provides (1) significant protection against
cGVHD in patients undergoing unrelated donor
bone marrow transplantation with CyA plus MTX
prophylaxis, (2) reduces the risk of chronic lung dys-
function, (3) improves quality of life, and (4) reduces
late transplant-related mortality. The latter point be-
came evident only after a median follow-up of 7 years,
because mortality because of cGVHD and CLD may
take years to become manifest.
Potential drawbacks of this study, performed in the
1990s, are the small number of patients; the possibility
of mismatched unrelated donors, according to current
typing techniques for HLA typing; the high number of
chronic myeloid leukemia patients; and the fact that 2
different doses of ATG were used (7.5 and 15 mg/kg).
However, in the update analysis [8], both doses of ATG
protected against cGVHD and CLD.
The second study to evaluate the effect of adding
ATG to conventional CyA 1 MTX was published
more recently [7]. In this study, 201 patients with
hematologic malignancies were randomized to receive
CyA and MTX with or without additional ATG-
fresenius (ATG-F) and were evaluable. The stem cell
source was peripheral blood (n 5 164; 82%) or bone
marrow (n 5 37; 18%), the donor type was unrelated,
and the conditioning regimen was myeloablative. The
analysis comprised 103 ATG-F patients and 98 con-
trols. The cumulative incidence of aGVHD grade
III–IV was 11.7% in the ATG-F group versus 24.5%
in the control group (P5 .054), and the cumulative in-
cidence of aGVHD grade II–IV was 33% in the ATG-
F group versus 51% in the control group (P 5 .011).
The 2-year cumulative incidence of extensive cGVHD
was 12.2% versus 42.6% (P 5 .0001).
This study has been updated and extensive
cGVHDat last follow-up was 45% for control patients
and 12% for ATG patients [9]. The authors conclude
that the addition of ATG-F to GVHD prophylaxis
with CyA and MTX decreases cGVHD significantly
and increases the proportion of patients alive without
immunosuppressive therapy.
It is striking that 2 separate prospective studies, 1
performed in the 1990s and 1 in the last decade, using
2 different ATG products (Thymoglobulin and ATG-
F), have produced nearly the same figures: The addi-
tion of ATG to a combination of CyA1MTX reduces
the risk of extensive cGVHD from 41% to 45% to
12% to 15%.
An additional randomized trial examined the effect
of marrow T cell depletion on the outcome of trans-
plantation. Although this study does not directly
address the question of whether anti-T cell antibodies
should be added to the transplant preparative regimen,
the results are nonetheless informative. In this study,
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German trial, patients were randomized in the United
States to receive a stem cell graft depleted of T cells
(TCD) or not [1]. The study showed a reduced risk
of aGVHD for patients receiving TCD grafts, but no
difference in cGVHD. This trial has several problems
that may explain the lack of efficacy on cGVHD. In the
first place, it compared CyA 1 MTX versus TCD 1
CyA: So instead of adding TCD to a standard regimen
(CyA 1 MTX), the study arm was devoid of MTX.
Second, the TCD methods were different and in-
cluded elutriation, the use of a monoclonal antibody,
or horse ATG. Third, the conditioning regimens
used for controls and TCD patients were different,
with increased intensity of the regimens administered
to TCD patients [10]. Therefore, no firm conclusion
as to the effect of ATG added to CyA 1 MTX can
be drawn from this study. The U.S. study did show
that T cell depletion, as provided by the study proto-
col, did not reduce cGVHD. The question as to
whether ATG added toCyA1MTX reduces cGVHD
was not directly asked.
The Italian and German trial instead show that
ATG (no matter what brand) added to a conventional
CyA 1 MTX regimen significantly reduces cGVHD,
and in the Italian trial, CLD. Also, the German trial
shows that control patients had more ‘‘respiratory
insufficiency’’ than in the ATG arm, although it is
not specified whether this was acute or chronic respira-
tory insufficiency.
CAMPATH
AlthoughCAMPATHhas been extensively used in
thousands of patients, there are no prospective ran-
domized trials comparing patients receiving or not re-
ceiving CAMPATH.
In single-arm studies, CAMPATHhas been shown
to prevent aGVHD and cGVHD, although some of
these studies have also shown an increased risk of
relapse.
Conclusions
T cell antibodies, and specifically ATG, reduce
aGVHD and cGVHD, as demonstrated in prospective
randomized trials. An increased risk of infections has
been documented in patients receiving ATG, in
particular, Epstein-Barr virus-related infections; this
problem can be addressed by using prophylactic or
preemptive rituximab.
Reduction of aGVHD and cGVHD does not nec-
essarily translate into a survival advantage in the short/
medium term (3-5 years), but may result in less
cGVHD-related deaths in the long term (beyond
5-10 years). Also, if survival is equivalent for patients
receiving or not receiving ATG, quality of life would
be expected to be superior in ATG patients becauseof the lower rate of cGVHD. So the answer to the
question, ‘‘Are T cell antibodies beneficial if used as
part of the preparative regimen in allogeneic HCT?’’
is yes in terms of GVHD, quality of life, and possibly
life expectancy.THE CASE AGAINSTANTI-T CELL
ANTIBODIES IN ALLOGENEIC HCT
For over 30 years, in vivo T cell depletion with
ATG preparations has been used by some groups
with hopes of reducing GVHD, enabling engraftment,
and limiting transplant-related mortality. Unfortu-
nately, after this long period of time, the benefits of
ATG have yet to be clearly established. Although
case series of transplantations that included ATG sug-
gested it may decrease GVHD, few adequately pow-
ered prospective randomized studies have been
conducted to address the true effect of ATG on out-
come.
One of the challenges in interpreting clinical
reports is the variety of ATG preparations in use.
ATG may be derived from horse or rabbit serum and
can be raised against distinct cellular targets. The dif-
ference in derivation of these products as well as the
various dose schedules employed in clinical trials
impact both the extent and specificity of T cell deple-
tion and immune reconstitution, consequently influ-
encing GVHD, infectious complications, relapse,
and survival.
Two small randomized trials reported from Italy
suggested that in patients undergoing myeloablative
transplantation from unrelated donors, a dose of
7.5 mg/kg thymoglobulin did not reduce rates of grade
III-IV aGVHD, whereas a significant reduction was
noted at a dose of 15 mg/kg. However, at the higher
dose, there was an increase in fatal infections, negating
any survival benefit for patients receiving thymoglobu-
lin. In addition, platelet recovery was impaired at the
higher dose level. Chronic GVHD incidence was sig-
nificantly lower in patients receiving thymoglobulin
[5]. A retrospective analysis of the use of ATG in mye-
loablative transplantation from France demonstrated
no significant reduction in grades III-IV aGVHD,
but a significant reduction in cGVHD [11]. In this re-
port, there was no benefit in terms of nonrelapse mor-
tality or overall survival (OS). A recent prospective
randomized trial from Europe in the myeloablative
setting compared no in vivo depletion versus in vivo
T cell depletion using an ATG preparation (Fresenius)
in 202 patients with hematologic malignancies [7]. In
this study, aGVHD and cGVHD were lower with
ATG. Relapse and nonrelapse mortality rates were
similar in the 2 cohorts, and there were no significant
differences in OS rates between ATG recipients and
those who did not receive ATG. Although these stud-
ies do suggest that ATG can reduce cGVHD, which
S114 Biol Blood Marrow Transplant 18:S111-S115, 2012F. R. Appelbaum et al.can be disabling for some patients, there is no indica-
tion that ATG preparations will improve survival.
In the past decade, there has been a dramatic
increase in the use of reduced-intensity conditioning
(RIC) for allogeneic transplantation. Based on experi-
ence in the myeloablative setting, ATG preparations
have been incorporated into RIC regimens by many
groups in the absence of any substantial prospective
data [12,13]. The success of RIC transplantation
relies on the integrity of graft-versus-tumor activity
because the cytoreductive effects of RIC are usually
insufficient to eradicate malignancy. As such, immune
manipulations that might weaken allo-immunity
might compromise the therapeutic effect of transplan-
tation. Recently, the Center for International Blood
and Marrow Transplant Research studied adult
patients undergoing RIC transplantation for hemato-
logic malignancies from 7-8/8 related and unrelated
donors [14]. This analysis included 584 patients in
whom ATG was administered and 879 in whom it
was not. Grade II-IV aGVHD was not impacted by
ATG (38% versus 40%), although cGVHD, as noted
in the ablative studies above, was lower in ATG recip-
ients (40% versus 52%). However, relapse was more
frequent with ATG compared with T cell–replete reg-
imens (51% versus 38%, respectively, P \ .001).
Moreover, nonrelapse mortality and Epstein-Barr
virus lymphoproliferative disease was higher with
ATG. Consequently, disease-free survival was lower
in ATG recipients (25% versus 39%, P \ .001) as
was OS (38% versus 46%). These results suggest
that in the RIC setting, although ATG may be associ-
ated with a lower risk of cGVHD, decreased immune
surveillance might negatively impact overall outcome.
At this point in time, there is insufficient evidence
to advocate for the routine use of ATG in allo-
transplantation, particularly in the reduced-intensity
study. However, transplant physicians are encouraged
to enroll their patients on well-designed prospective
randomized trials to definitively address the question
of ATG and its role in improving quality of life and
survival.DISCUSSION
Any good debate should begin with a definition of
terms. One of the difficulties in deciding the role of
anti-T cell antibodies as part of a preparative regimen
is the variability in the studies so far performed, partic-
ularly with regard to the form of antibody, the type of
preparative regimen, and the source of stem cells. At
least 4 different preparations of anti-T cell globulins
are now commercially available: ATG-F, which is
produced by immunizing rabbits with the Jurkat
human T-lymphoblastic cell line; thymoglobulin,
which is produced by immunizing rabbits with human
thymocytes; and ATGAM and lymphoglobulin, whichare produced by immunizing horses with human thy-
mocytes. Because they are produced in different
ways, it is not surprising that these different types of
ATG contain variable specificities and amounts of
antibodies. The cytotoxicities of these 4 ATGs on T
cells are roughly similar; however, the clinically
achievable concentrations of these agents vary consid-
erably from about 75 mg/mL for thymoglobulin to up
to 1000 mg/mL for ATG-F. However, it is becoming
clear that T cell depletion is only part of the effect of
these preparations. The recent report showing that
horse-derived ATGAM is more effective than the rab-
bit ATG thymoglobulin in the treatment of aplastic
anemia, despite the fact that the rabbit product pro-
duces more profound and prolonged lymphopenia,
brings home the fact that we do not completely under-
stand the biologic effects of these complex antibody
mixtures [15]. Until we do, we should probably refrain
from extrapolating the results of a study involving 1
ATG preparation to results with others, no matter
how intuitively appealing it might be.
The transplant setting in which the reagent is
tested almost certainly makes a difference as well.
Dr. Bacigalupo’s compelling arguments for the use
of ATG were mostly based on clinical trials involving
myeloablative conditioning regimens. It is reassuring
that in that setting, the decreased incidence of grade
III-IV aGVHD and cGVHD was not offset by an
increase in relapse rates. The majority of patients
(64%) in the treatment group had early-stage disease,
and so it is uncertain if an impact on relapse would
emerge among higher-risk patients. In contrast, Dr.
Soiffer’s analysis of the impact of anti-T cell antibodies
in transplant recipients receiving RIC found a striking
increase in relapse with CAMPATH or ATG versus
T-replete transplants (relapse rates 49%, 51%, and
38%, respectively, P\ .001). The increase in relapse
rates and opportunistic infections when anti-T cell
antibodies were included in reduced-intensity regi-
mens resulted in inferior OS and suggests that such
antibodies should not be routinely used in this setting.
Finally, the source of stem cells also likely affects
the impact of the inclusion of anti-T cell antibodies.
The majority of patients entered into the studies cited
by Bacigalupo and Soiffer above received transplants
from unrelated donors. In analyses available to date,
no large difference in the effects of ATG depending
on donor source (related versus unrelated) were noted,
but the studies were not designed or sized to detect
possible differences. In the myeloablative studies cited
by Bacigalupo, there was variability in the use of either
bonemarrow or peripheral blood stem cells. A recently
completed Bone and Marrow Transplant Clinical
Trials Network randomized trial has shown increased
cGVHD and no survival advantage with the use of
peripheral blood versus bone marrow for unrelated
donor transplants. ATG was not part of this trial.
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peripheral blood with ATG is equivalent or better
than marrow with or without ATG is untested.ACKNOWLEDGMENTS
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